Search Results - "Ghalaiyini, Riham"

Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein by van Schooten, Jelle, Farokhi, Elinaz, Schorcht, Anna, van den Kerkhof, Tom L. G. M., Gao, Hongmei, van der Woude, Patricia, Burger, Judith A., Meesters, Tim G. Rijkhold, Bijl, Tom, Ghalaiyini, Riham, Turner, Hannah L., Dorning, Jessica, van Schaik, Barbera D. C., van Kampen, Antoine H. C., Labranche, Celia C., Stanfield, Robyn L., Sok, Devin, Montefiori, David C., Burton, Dennis R., Seaman, Michael S., Ozorowski, Gabriel, Wilson, Ian A., Sanders, Rogier W., Ward, Andrew B., van Gils, Marit J.

“…A major goal of current HIV-1 vaccine design efforts is to induce broadly neutralizing antibodies (bNAbs). The VH1-2-derived bNAb IOMA directed to the…”
Get full text

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer by van Schooten, Jelle, Schorcht, Anna, Farokhi, Elinaz, Umotoy, Jeffrey C, Gao, Hongmei, van den Kerkhof, Tom L G M, Dorning, Jessica, Rijkhold Meesters, Tim G, van der Woude, Patricia, Burger, Judith A, Bijl, Tom, Ghalaiyini, Riham, Torrents de la Peña, Alba, Turner, Hannah L, Labranche, Celia C, Stanfield, Robyn L, Sok, Devin, Schuitemaker, Hanneke, Montefiori, David C, Burton, Dennis R, Ozorowski, Gabriel, Seaman, Michael S, Wilson, Ian A, Sanders, Rogier W, Ward, Andrew B, van Gils, Marit J

“…Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subtypes and are able to prevent HIV-1 infection in animal…”
Get full text

Identification of $\mathrm{IOMA}$-class neutralizing antibodies targeting the $\mathrm{CD4}$-binding site on the $\mathrm{HIV}$-1 envelope glycoprotein by van Schooten, Jelle, Farokhi, Elinaz, Schorcht, Anna, van den Kerkhof, Tom L. G. M., Gao, Hongmei, van der Woude, Patricia, Burger, Judith A., Meesters, Tim Rijkhold, Bijl, Tom, Ghalaiyini, Riham, Turner, Hannah L., Dorning, Jessica, van Schaik, Barbera D. C., van Kampen, Antoine H. C., Labranche, Celia C., Stanfield, Robyn L., Sok, Devin, Montefiori, David C., Burton, Dennis R., Seaman, Michael S., Ozorowski, Gabriel, Wilson, Ian A., Sanders, Rogier W., Ward, Andrew B., van Gils, Marit J.

“…A major goal of current HIV-1 vaccine design efforts is to induce broadly neutralizing antibodies (bNAbs). The VH1-2-derived bNAb IOMA directed to the…”
Get full text